STUDY QUESTION: Is there a benefit to assessing ploidy in delayed embryos reaching the morula stage on Day 6 of development?
Introduction
Preimplantation genetic testing for aneuploidy (PGT-A), as well as embryo morphology and morphokinetics, has enhanced embryo selection (Meseguer et al., 2011; Yang et al., 2012; Forman et al., 2013; Scott et al., 2013a; Rubio et al., 2017) . PGT-A was originally performed using fluorescent in situ hybridization (FISH) to analyze a few chromosomes of the biopsied polar body or blastomere(s) of the cleavage-stage embryo (Munne et al., 1993; Verlinsky et al., 1995) . The introduction of trophectoderm (TE) biopsy along with comprehensive chromosome screening platforms (array comparative genomic hybridization, next-generation sequencing, single nucleotide polymorphism array and quantitative PCR) has improved this technique Treff et al., 2010; Yang et al., 2012; Scott et al., 2013b; Goodrich et al., 2016) . Four RCTs examining the role of PGT-A using comprehensive chromosome screening demonstrated that it increased implantation rates (IRs) per transfer and decreased pregnancy loss rates, especially in older women (Yang et al., 2012; Forman et al., 2013; Scott et al., 2013a; Rubio et al., 2017) .
Embryo development and morphology have been shown to correlate with aneuploidy and pregnancy rates (Alfarawati et al., 2011; Fragouli et al., 2014 Fragouli et al., , 2008 . Indeed, blastocyst-stage embryos have a lower incidence of aneuploidy compared to cleavage-stage counterparts . In addition, fully expanded blastocysts are associated with lower aneuploidy rates than early-stage blastocysts (Alfarawati et al., 2011; Fragouli et al., 2014) . However, the implantation potential of slow-developing embryos reaching the morula stage on Day 6, delayed by~48 h, is largely unknown.
While PGT-A is preferentially performed in embryos that have reached the blastocyst stage by Day 5 or 6, slow-developing embryos are typically deselected and discarded, resulting in a smaller cohort of embryos deemed suitable for biopsy (Yang et al., 2012; Scott et al., 2013a) . Determining the viability of slow-developing embryos is particularly relevant for women undergoing PGT-A who have diminished ovarian reserve and a relatively low blastocyst yield. With this in mind, we aimed to compare the aneuploidy and IRs of embryos reaching the morula stage on Day 6 to those of their sibling blastocysts.
Materials and Methods

Cycle selection
The Weill Cornell Medicine Institutional Review Board approved this study. All patients undergoing PGT-A at the Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine from January 2013 through December 2016 were reviewed for inclusion. All patients who had a biopsy of a cavitating or compacted morula on Day 6 were included. The aneuploidy and pregnancy rates were compared between compacted morulae, cavitating morulae and their sibling blastocysts.
Clinical protocol
Controlled ovarian stimulation, trigger of final oocyte maturation, oocyte retrieval, culture and embryo transfer were performed per our standard protocols (Huang and Rosenwaks, 2014) . Ovarian stimulation was achieved by daily administration of exogenous gonadotrophins (Gonal-F, EMD-Serono Inc., Rockland, MA, USA; Follistim, Merck, Kenilworth, NJ, USA; and Menopur, Ferring Pharmaceuticals Inc., Parsippany, NJ, USA). Gonadotrophin doses were determined according to patient age, weight, markers of ovarian reserve (antral follicle count and serum anti-Müllerian hormone levels) and previous response to stimulation. We used GnRHantagonist (Ganirelix acetate, Merck; or Cetrotide, EMD-Serono Inc.) to attain pituitary suppression for the majority of cycles. Alternatively, GnRHagonist (leuprolide acetate, Abbott Laboratories, Chicago, IL, USA) downregulation was employed. Transvaginal ultrasounds and serial estradiol (E2) levels were performed to carefully monitor the response to stimulation. The gonadotrophin dose was then adjusted accordingly. HCG (Novarel, Ferring Pharmaceuticals Inc.) and/or GnRH-agonist (leuprolide acetate, Abbott Laboratories) were administered when two or more follicles reached ≥17 mm diameter to trigger final oocyte maturation. Ultrasound-guided transvaginal oocyte retrieval was performed under conscious sedation 35-37 h after trigger.
Embryos were cryopreserved after biopsy and subsequently transferred in frozen-thawed embryo transfer (FET) cycles. In general, women with regular menstrual cycles and normal mid-luteal progesterone levels underwent natural FET cycles in which they were monitored with transvaginal ultrasounds and serial measurements of E2 and LH levels. The transfer of euploid embryo(s) was performed 5 days after the LH surge. Some women, based on physician preference, received vaginal progesterone supplementation (Endometrin, Ferring Pharmaceuticals Inc.) after the transfer. Alternatively, patients for whom natural-cycle FET was not ideal underwent programmed cycles in which patches with an escalating dose of E2 were applied for~14 days. After an endometrial thickness of ≥7 mm was reached, intramuscular progesterone supplementation was initiated along with a reduction in E2 to 0.2 mg daily. Hormonal levels were monitored throughout the cycle to ensure adequacy of supplementation. Following 5 days of progesterone supplementation, embryos were transferred using Wallace catheters (Smiths Medical Inc., Norwell, MA, USA).
Laboratory protocol
Embryos were cultured in sequential culture media using the EmbryoScope (Vitrolife, Sweden) time-lapse system and were graded on Day 5 or 6 immediately before biopsies were performed. The majority of biopsied embryos were blastocysts, and the rest were morulae (compacted or cavitating).
Morulae that had a group of tightly packed cells after completing the fourth division (16 cells) were classified as compacted (Fig. 1 ). Those exhibiting a cavity (filling <50% of the embryo volume) without a clear definition of the inner cell mass (ICM) and TE cells were classified as cavitating (Fig. 1 ). Blastocysts were defined as embryos with a blastocoel filling >50% of the cavity and ICM cells that can be differentiated from TE cells (Fig. 1 ). Biopsies were performed in the standard fashion: After immobilizing the embryo with a holding pipette, the zona pellucida was perforated by laser pulses (ZI-LOStk Laser, Hamilton Thorne, Beverly, MA, USA), and three to seven cells were aspirated by a biopsy pipette with a 20-μm internal diameter. After exposing the biopsied specimens to wash buffer (PBS supplemented with 2% polyvinylpyrrolidone and 3% bovine serum albumin), the cells were placed in 0.2 mL PCR tubes with 2 μL lysis buffer (SurePlex DNA Amplification System, Illumina, CA, USA). The PGS team at Weill Cornell analyzed the specimens using the Illumina 24SureV3 chip (BlueGnome, Cambridge, UK) (array comparative genomic hybridization). Embryos were vitrified after biopsy.
Study variables
The primary outcomes of this study were the aneuploidy rate and IR . The secondary outcomes were the live birth rate (LBR) and spontaneous abortion (SAB) rate. The LBR was defined as the proportion of cycles resulting in a live birth. The IR was calculated by dividing the number of intrauterine gestational sacs observed on ultrasound by the number of embryos transferred. The SAB rate was defined as the proportion of clinical pregnancies (gestational sacs visualized on ultrasound) resulting in miscarriage. The aneuploidy rate was compared between compacted morulae, cavitating morulae, and their sibling blastocysts. The chromosomes involved in the aneuploidy and the complexity of aneuploid errors (single, dual or complex [three or more chromosomes]) were also compared between embryos of different developmental stages. The pregnancy outcomes resulting from the transfer of euploid morulae were compared to those obtained after the transfer of euploid blastocysts.
Statistical analysis
Chi-square (χ 2 ) and Fisher's exact tests were used to compare the categorical variables, which were expressed as percentages. The continuous variables were tested for normality and were expressed as mean ± SD. Student's t test was used for parametric data. Odds ratios (ORs) with 95% CIs were calculated. Multiple logistic regression was used to adjust the ORs for several confounding factors including age, BMI, number of transferred embryos, type of frozen cycle (natural versus programmed), peak endometrial thickness, and total number of euploid embryos for each patient. A P value of 0.05 was used as a cutoff for statistical significance. Data analysis was performed using STATA statistical software version 14 (StataCorp LLC, TX, USA)
Results
The study included 763 cycles in which 1260 morulae (872 cavitating and 388 compacted) and 3014 blastocysts were biopsied. The mean female age was 38.1 ± 4.5 years, gravidity was 1.9 ± 1.6, parity was 0.4 ± 0.6 and BMI was 23.4 ± 4 kg/m 2 . The mean male partner age was 40.6 ± 7.1 years.
There was a significant difference in the aneuploidy rates between compacted morulae (88.1%), cavitating morulae (77.5%) and sibling blastocysts (57.4%) (P < 0.001) (Fig. 2) . Comparable differences in aneuploidy rates were seen between compacted morulae, cavitating morulae, and blastocysts in the four age groups (<35, 35-37, 38-39 and ≥40 years) (P < 0.001) ( Table I ). Of note, the majority of compacted morulae (98.1%) and cavitating morulae (91.6%) were aneuploid in women ≥40 years old.
Regarding the nature of aneuploid errors, blastocysts had a significantly lower rate of complex aneuploidy (25%) compared with cavitating (39%) and compacted morulae (48%) (P < 0.001). Besides chromosome 19, which was more frequently involved in the aneuploidy of cavitating morulae compared to blastocysts (8.0 versus 5.6%, P = 0.001), the chromosomes were similarly affected in blastocysts, compacted and cavitating morulae (Table II) .
We reviewed the FET outcomes of 376 cycles in which euploid blastocysts were transferred and 39 cycles in which euploid morulae were transferred (27 cavitating morulae and 12 compacted morulae). The demographic parameters of patients in both groups (morulae transfer and blastocyst transfer) are summarized in Table III . Morulae yielded an acceptable but significantly lower IR (28.2 versus 54.6%; P = 0.002; adjusted OR = 0.29; 95% CI = 0.1-0.6) and LBR (23.1 versus 55.0%, P = 0.001; adjusted OR = 0.23; 95% CI = 0.1-0.5) compared to blastocysts (Table III) . These ratios were adjusted for age, BMI, number of Figure 1 Representative microscopy images of biopsied human embryos. Morulae that had a group of tightly packed cells after completing the fourth division (16 cells) were classified as compacted. Those exhibiting a cavity (filling <50% of the embryo volume) without a clear definition of the inner cell mass (ICM) and trophectoderm (TE) cells were classified as cavitating. Blastocysts were defined as an embryo with a blastocoel filling >50% of the cavity and ICM cells that can be differentiated from TE cells. Magnification: ×200. Figure 2 The aneuploidy rates of human compacted morulae (n = 388), cavitating morulae (n = 872) and sibling blastocysts (n = 3014). Chi-square test was used to compare the percentages. *P < 0.001. transferred embryos, type of frozen cycle, peak endometrial thickness and total number of euploid embryos for each patient. Cavitating morulae and compacted morulae yielded comparable IRs (29.6 versus 25%; P = 0.7) and LBRs (22.2 versus 25%; P = 0.8). There was no significant difference in the SAB rate between euploid morulae and blastocysts (18.1 versus 8.0%; P = 0.2). 
Discussion
This study investigated the significance of testing embryos that reach the morula stage on Day 6. Although the euploidy rates of blastocysts were higher compared to morulae, our data show that Day-6 morulae had acceptable euploidy rates in women <40 years old. Furthermore, euploid morulae (compacted or cavitating) yielded a reasonable IR and LBR.
Preimplantation chromosomal analysis technology has improved over the last 2 decades. The original testing method, which used FISH on blastomeres of cleavage-stage embryos, was often harmful (Mastenbroek et al., 2007 (Mastenbroek et al., , 2011 Scott et al., 2013b) . The introduction of comprehensive chromosome screening with TE biopsy has partially overcome the pitfalls of this technique (Yang et al., 2012; Forman et al., 2013; Scott et al., 2013a Scott et al., , 2013b Rubio et al., 2017) . A randomized trial of 103 good-prognosis patients (age < 35 years, first IVF cycle and no prior miscarriage) showed that PGT-A yielded an increase in the ongoing pregnancy rate per transfer (Yang et al., 2012) . A recent trial including women of advanced maternal age (38-41 years old) showed that PGT-A decreases miscarriage rates and improves delivery rates after the first transfer .
Despite the continuous enhancement of this technology, it remains imperfect. For instance, TE biopsy, which has been to shown to be safer than cleavage-stage embryo biopsy, can increase the miscarriage rate of euploid embryos up to 25% when more than 10 cells are biopsied (Ten et al., 2015) . In addition, false-positive results can occur due to biological origins (i.e. mosaicism) or technical errors Goodrich et al., 2016; Gleicher and Orvieto, 2017; Vera-Rodriguez and Rubio, 2017) . Furthermore, data on the short-and long-term effects of mosaicism are lacking; thus, many clinicians are either not transferring mosaic embryos or selecting mosaicism thresholds above which they do not transfer the embryos (Hulten et al., 2013; Vera-Rodriguez and Rubio, 2017; Weissman et al., 2017) . Therefore, it is critical to prevent the loss of additional potentially viable embryos. Our data show that Day-6 morulae in women <40 years old can result in a reasonable LBR and therefore should be biopsied for women undergoing PGT-A. This is especially relevant for women who have a limited number of embryos, as doing so could reduce the loss of viable embryos and increase the patient's chances of achieving a successful pregnancy.
The higher aneuploidy rate of Day-6 morulae compared to blastocysts is expected due to the documented effect of ploidy on embryo development (Rubio et al., 2007; Alfarawati et al., 2011; Fragouli et al., 2014; Vega et al., 2014; Minasi et al., 2016) . It has been shown that blastocysts with the highest morphology scores as well as embryos that progress faster to the blastocyst stage are more likely to be euploid compared to other embryos (Rubio et al., 2007; Alfarawati et al., 2011; Fragouli et al., 2014; Vega et al., 2014; Minasi et al., 2016) . Furthermore, the morphological grading of euploid blastocysts has been correlated with the implantation potential of these embryos (Irani et al., 2017) . For instance, excellent quality euploid blastocysts have been associated with a significantly higher ongoing pregnancy rate compared to good, average and poor quality euploid blastocysts (Irani et al., 2017) . These data explain the difference we found in the IRs and LBRs between euploid morulae and euploid blastocysts. Given the low euploidy rates (6.4%) of Day-6 morulae in women ≥40 years old, it may not be beneficial to biopsy these embryos in this population.
The majority of aneuploidy of Day-6 morulae involved three or more chromosomes (39-48%) while 48% of blastocysts had a single chromosome aneuploidy. This could be explained by the higher levels of meiotic errors or maybe lower ability to self-correct errors in slowdeveloping embryos compared with faster counterparts.
A potential drawback of biopsying embryos at the morula stage, especially compacted morulae, is the inability to distinguish between ICM and TE cell origin. At the morula stage, cell lineage differentiation has not occurred and biopsied cells can be undifferentiated blastomeres or future ICM or TE cells (Shahbazi et al., 2016) . In addition, removing a few cells from a morula (comprising 16-32 cells) might be detrimental to embryo viability. Furthermore, the biopsy of morula-stage embryos can include cells that are not going to participate in embryo development and are frequently observed as extruded cells. These cells are not usually euploid and do not represent the chromosomal status of the embryo; they might represent embryo 'self-correction' (Lagalla et al., 2017) . A possible method to overcome this limitation would be to culture Day-6 morulae for one additional day and to biopsy those reaching blastocyst on Day 7. Given that our clinic does not routinely culture embryos to Day 7, we are not able to comment on the potential proportion of Day 6 morulae that would achieve this milestone.
Although this study included a large number of morulae and blastocysts, the sample size of euploid morula transfer cycles was limited owing to the relatively high aneuploidy rate of these embryos as well ) and Fisher's exact tests were used to compare the categorical variables, which were expressed as percentages. The continuous variables were tested for normality and expressed as mean ± SD. Student's t test was used for parametric data.
as the presence, in the majority of cases, of sibling euploid blastocysts that were preferentially selected for transfer. Thus, a larger cohort would be beneficial to validate the reassuring LBRs and SAB rates reported in this study. Furthermore, internal data analysis is suggested to determine the reproducibility of our findings at different centers, especially given the inherent subjectivity of morphological assessment. Moreover, we should emphasize that, although the mean number of transferred blastocysts was 1.2 in this selected cohort, single embryo transfer is our recommendation for all women undergoing PGT-A.
In conclusion, Day-6 morulae can be euploid and have an acceptable implantation potential in women <40 years old. They might offer many women, especially those with diminished ovarian reserve, the only opportunity to achieve their dream of having a biological child. Women who have both euploid blastocysts and morulae should preferentially transfer a blastocyst, as they convey higher IRs compared to euploid morulae. However, testing Day-6 morulae should be considered, particularly for women <40 years old who are undergoing PGT-A with a small cohort of blastocysts.
